|
AstraZeneca Buys Rights to Synairgen Asthma Compound
Genetic Engineering News SNG001 is an inhaled interferon beta (IFN-beta) for respiratory tract viral infections in patients with severe asthma. AstraZeneca said it plans early next years to launch a Phase IIa study of SNG001 in patients with severe asthma—a trial it said … |
View full post on asthma – Google News